Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Chang, Vicky C.; Khan, Ali A.; Huang, Wen‐Yi; Katki, Hormuzd A.; Purdue, Mark P.; Landgren, Ola; Hofmann, Jonathan N.

doi:10.1038/s41408-022-00642-4

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also showed that the addition of classical immunoparesis to the previous set of prognostic variables increases the discriminatory power of the model, helping to identify high-risk (vs low-risk) MGUS patients [ 12 ]. Additional variables may be considered to reach a more precise prediction [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ], although the role of some of them remains controversial. For this reason, patients must be followed in a risk-adapted approach, although follow-up recommendations are heterogeneous [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal

Ríos-Tamayo

Lahuerta

Martínez‐López

et al. 2022

Cancers

View full text Add to dashboard Cite

Monoclonal gammopathies of clinical significance (MGCSs) represent a group of diseases featuring the association of a nonmalignant B cells or plasma cells clone, the production of an M-protein, and singularly, the existence of organ damage. They present a current framework that is difficult to approach from a practical clinical perspective. Several points should be addressed in order to move further toward a better understanding. Overall, these entities are only partially included in the international classifications of diseases. Its definition and classification remain ambiguous. Remarkably, its real incidence is unknown, provided that a diagnostic biopsy is mandatory in most cases. In fact, amyloidosis AL is the final diagnosis in a large percentage of patients with renal significance. On the other hand, many of these young entities are syndromes that are based on a dynamic set of diagnostic criteria, challenging a timely diagnosis. Moreover, a specific risk score for progression is lacking. Despite the key role of the clinical laboratory in the diagnosis and prognosis of these patients, information about laboratory biomarkers is limited. Besides, the evidence accumulated for many of these entities is scarce. Hence, national and international registries are stimulated. In particular, IgM MGCS deserves special attention. Until now, therapy is far from being standardized, and it should be planned on a risk and patient-adapted basis. Finally, a comprehensive and coordinated multidisciplinary approach is needed, and specific clinical trials are encouraged.

show abstract

Section: Introductionmentioning

confidence: 99%

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal

Ríos-Tamayo

Lahuerta

Martínez‐López

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Similarly, a retrospective study from the US Veterans Health Administration in 2017 showed weight status and obesity are both associated with increased risk of transformation of MGUS to MM (21). Most recently, a retrospective analysis in 2022 within the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial revealed a 35% increase in odds of progression from non-IgM MGUS to MM with each 5 kg/m 2 increase in BMI (22).…”

mentioning

confidence: 99%

Obesity and myeloma: Clinical and mechanistic contributions to disease progression

et al. 2023

View full text Add to dashboard Cite

Obesity and obesogenic behaviors are positively associated with both monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM). As the only known modifiable risk factor, this association has emerged as a new potential target for MM prevention, but little is known about the mechanistic relationship of body weight with MM progression. Here we summarize epidemiological correlations between weight, body composition, and the various stages of myeloma disease progression and treatments, as well as the current understanding of the molecular contributions of obesity-induced changes in myeloma cell phenotype and signaling. Finally, we outline groundwork for the future characterization of the relationship between body weight patterns, the bone marrow microenvironment, and MM pathogenesis in animal models, which have the potential to impact our understanding of disease pathogenesis and inform MM prevention messages.

show abstract